169 related articles for article (PubMed ID: 20450868)
1. Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.
Ragupathi G; Damani P; Deng K; Adams MM; Hang J; George C; Livingston PO; Gin DY
Vaccine; 2010 Jun; 28(26):4260-7. PubMed ID: 20450868
[TBL] [Abstract][Full Text] [Related]
2. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
[TBL] [Abstract][Full Text] [Related]
3. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
[TBL] [Abstract][Full Text] [Related]
4. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
5. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of potent Quillaja saponin vaccine adjuvants.
Adams MM; Damani P; Perl NR; Won A; Hong F; Livingston PO; Ragupathi G; Gin DY
J Am Chem Soc; 2010 Feb; 132(6):1939-45. PubMed ID: 20088518
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of widely consumed botanicals as immunological adjuvants.
Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
[TBL] [Abstract][Full Text] [Related]
10. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.
Deng K; Adams MM; Damani P; Livingston PO; Ragupathi G; Gin DY
Angew Chem Int Ed Engl; 2008; 47(34):6395-8. PubMed ID: 18624313
[No Abstract] [Full Text] [Related]
12. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
13. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
14. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.
Livingston PO; Adluri S; Helling F; Yao TJ; Kensil CR; Newman MJ; Marciani D
Vaccine; 1994 Nov; 12(14):1275-80. PubMed ID: 7856291
[TBL] [Abstract][Full Text] [Related]
16. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
17. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
Ragupathi G; Gardner JR; Livingston PO; Gin DY
Expert Rev Vaccines; 2011 Apr; 10(4):463-70. PubMed ID: 21506644
[TBL] [Abstract][Full Text] [Related]
18. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure verification of the vaccine adjuvant QS-7-Api. Synthetic access to homogeneous Quillaja saponaria immunostimulants.
Deng K; Adams MM; Gin DY
J Am Chem Soc; 2008 May; 130(18):5860-1. PubMed ID: 18410100
[TBL] [Abstract][Full Text] [Related]
20. Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis.
Fernández-Tejada A; Tan DS; Gin DY
Acc Chem Res; 2016 Sep; 49(9):1741-56. PubMed ID: 27568877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
